Contact Us: 01282 426380
KM Financial Solutions | Roche’s Alecensa wins EU panel’s nod against mutated lung cancer
1591
post-template-default,single,single-post,postid-1591,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

Roche’s Alecensa wins EU panel’s nod against mutated lung cancer

12 Oct Roche’s Alecensa wins EU panel’s nod against mutated lung cancer

Posted at 12:14h in News by
0 Likes
ZURICH, Oct 13 (Reuters) – Swiss drugmaker Roche’s
Alecensa has been recommended for approval in Europe as a
first-line treatment for mutated lung cancer, a key European
Medicines Agency (ESA) experts panel said on Friday.

No Comments

Post A Comment